Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees
Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 employees as part of a reorganization plan that aims to focus on the launch of its postpartum depression pill.
Sage Therapeutics to lay off one-third of workforce
After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its leadership team.
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and Alzheimer's treatments.
Sage Therapeutics to lay off more than 165 employees
Sage Therapeutics said on Thursday it will lay off more than 165 employees, or about 33% of the company's total workforce, as part of a reorganization plan. The drugmaker plans to prioritize the launch of postpartum depression treatment Zurzuvae,
Sage Therapeutics to lay off one-third staff under reorganization
Sage Therapeutics (NASDAQ:SAGE) announced a reorganization, including a workforce reduction of about 33%, to support the ongoing launch of ZURZUVAE for postpartum depression and to focus on pipeline development ahead of a clinical readout for dalzanemdor in Huntington’s Disease expected later this year.
Sage Therapeutics’ stock falls 4.7% as biotech unveils plan to cut 33% of workforce
Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...
pharmaphorum3h
Sage cuts a third of its workforce after R&D setbacks
Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...
FierceBiotech22h
Sage lays off half of R&D team, shakes up C-suite again
Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...
SAGE Therapeutics’ Strategic Reorganization and Cautious Hold Rating Amid Development Setbacks
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...
Sage Cuts One-Third of Workforce After Clinical Trial Setbacks
Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple ...
BioPharma Dive17h
Sage to cut one-third of workforce, streamline drug pipeline
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...
Sage Therapeutics Cutting Workforce by 33% -- Update
Sage and Biogen last year won Food and Drug Administration approval of Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major depressive disorder, a much ...
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc ...